{"id":201821,"name":"EMERGENT BIOSOLUTIONS INC.","slug":"emergent-biosolutions-inc","state":"DC","country":"United States of America","description":"biopharmaceutical company","totalSpending":650000,"filings":13,"yearlySpending":[{"year":2018,"income":200000},{"year":2019,"income":200000},{"year":2020,"income":200000},{"year":2021,"income":50000}],"issues":["BUD","DEF","HCR","HOM"],"firms":["MILNE, WIENER & SHOFE GLOBAL STRATEGIES (FKA M & W GOVERNMENT AFFAIRS, LLC)"],"lobbyists":["JOHN MILNE","JEFFREY WIENER"],"govEntities":["Health & Human Services, Dept of (HHS)","HOUSE OF REPRESENTATIVES","SENATE"],"sampleDescriptions":["FY 2018 Appropriations - provisions related to development, acquisition, and stockpiling of medical countermeasures for the U.S. Government\n\nFY 2019 Appropriations - provisions related to development,","H.R.2810 - National Defense Authorization Act for Fiscal Year 2018, provisions related to biological and chemical defense","Issues related to homeland security, emergency preparedness and response, the reauthorization of the Pandemic and All-Hazards Preparedness Act, and the strategic national vaccine stockpile.","Issues related to homeland security, emergency preparedness and response, the reauthorization of the Pandemic and All-Hazards Preparedness Act, and the strategic national vaccine stockpile.","Issues related to homeland security, emergency preparedness and response, the reauthorization of the Pandemic and All-Hazards Preparedness Act, and the strategic national vaccine stockpile."],"years":[2018,2019,2020,2021]}